"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 2 | 5 |
| 1999 | 3 | 4 | 7 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 6 | 0 | 6 |
| 2017 | 4 | 2 | 6 |
| 2018 | 6 | 1 | 7 |
| 2019 | 6 | 2 | 8 |
| 2020 | 11 | 5 | 16 |
| 2021 | 12 | 6 | 18 |
| 2022 | 6 | 1 | 7 |
| 2023 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. AIDS. 2023 09 01; 37(11):1711-1714.
-
PrEP Persistence Support and Monitoring in Areas of High HIV Burden in the Midwestern United States. AIDS Educ Prev. 2023 Jun; 35(3):235-246.
-
POWER Up-Improving pre-exposure prophylaxis (PrEP) uptake among Black cisgender women in the Southern United States: Protocol for a stepped-wedge cluster randomized trial (SW-CRT). PLoS One. 2023; 18(5):e0285858.
-
Residents and Fellows’ Confidence in Prescribing Pre-exposure Prophylaxis (PrEP) Acad Pediatr. 2023 08; 23(6):1282-1287.
-
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023 02 18; 76(4):720-729.
-
Routine, Opt-Out, Emergency Department Syphilis Testing Increases HIV Preexposure Prophylaxis Uptake. Sex Transm Dis. 2023 05 01; 50(5):292-297.
-
Examining the Awareness, Acceptability, and Adoption of Conventional and non-conventional Forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among jail-involved Black Sexual Minority men (BSMM) and Black Transgender Women (BTW) in Two Diverse US Cities. AIDS Behav. 2023 Apr; 27(4):1304-1313.
-
PrEP Use and Adherence among Transgender Persons in Chicago, IL (SHIPP Study, 2014-2018, USA). AIDS Behav. 2023 Mar; 27(3):901-908.
-
Provider Perspectives on Factors Affecting the PrEP Care Continuum Among Black Cisgender Women in the Midwest United States: Applying the Consolidated Framework for Implementation Research. J Acquir Immune Defic Syndr. 2022 07 01; 90(S1):S141-S148.
-
Sleep Disturbance is Associated with Missing PrEP Doses Among Young Black Sexual Minority Men in The N2 study. AIDS Behav. 2022 Dec; 26(12):3827-3833.